2024-513023-17-00招募中3 期
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.
MaaT PHARMA, MaaT PHARMA50 个研究点 分布在 6 个国家目标入组 73 人开始时间: 2024年7月18日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 73
- 试验地点
- 50
- 主要终点
- To evaluate the efficacy of MaaT013 assessed by the overall response rate (ORR) of gastrointestinal (GI) acute grfat-versus-host disease (aGVHD) response at day 28 (D28).
研究概览
简要总结
To evaluate the efficacy of MaaT013 assessed by the overall response rate (ORR) of gastrointestinal (GI) acute graft-versus-host disease (aGVHD) response at day 28 (D28).
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Long-term follow-up
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18 years old
- •Allo-HSCT with any type of donor, stem cell source, GvHD prophylaxis or conditioning regimen.
- •Acute GvHD episode with GI involvement per MAGIC guidelines (= grades II to IV), with or without involvement of other organs (Harris et al. 2016).
- •Patients resistant to steroids AND either resistant to OR with intolerance to ruxolitinib (intolerant patients: who had grade 3 or higher treatment-emergent and ruxolitinib-attributed adverse event that did not resolve within 7 days of discontinuing ruxolitinib): Resistance to steroids is defined as any of the following: - Lack of improvement (i.e., no decrease in stage in at least 1 involved organ system) after ≥ 5 days of treatment with CS at 2mg/kg/d methylprednisolone equivalent dose, - Progression (i.e., increase in any organ system or any new organ involvement) after ≥ 3 days of treatment with CS at 2 mg/kg/d methylprednisolone equivalent dose, - Patients treated with 1 mg/kg/d of CS because the physician deemed they would not tolerate 2 mg/kg/d and who correspond to the definition of SR patients, - Patients who previously began CS therapy at a lower dose (at least 1 mg/kg/d methylprednisolone equivalent) for skin or upper GI GvHD but develop new GvHD in another organ system, - Patients who cannot tolerate corticosteroid tapering, i.e., begin of CS at 2.0 mg/kg/d, demonstrate response, but show disease progress before a 50% decrease from the initial starting dose of CS is achieved. Resistance to ruxolitinib is defined as any of the following (Mohty et al. 2020): - Progression of GvHD compared to baseline after at least 5 days of treatment with ruxolitinib, based either on objective increase in stage/grade, or new organ involvement; - Lack of improvement in GvHD (partial response or better) compared to baseline after at least 14 days of treatment with ruxolitinib; - Loss of response, defined as objective worsening of GvHD determined by increase in stage, grade or new organ involvement at any time after initial improvement - Absence of complete response or very good partial response at day 28 after ruxolitinib Intolerance to ruxolitinib is defined as: - GvHD manifestations that persist without improvement in patients who had grade 3 or higher treatment-emergent and ruxolitinib-attributed adverse event that did not resolve within 7 days of discontinuing ruxolitinib.
- •Signature of informed and written consent by the subject or by the subject’s legally acceptable representative for patients under guardianship or trusteeship.
排除标准
- •Patients with known hypersensitivity to vancomycin or to any of the excipients listed in the corresponding SmPC
- •Absolute neutrophil count <500/μL, confirmed within 3 days prior to pre-treatment start. Use of growth factor supplementation is allowed.
- •Absolute platelet count < 10 000/μL, confirmed within 3 days prior to pre-treatment start. Use of platelet infusion is allowed.
- •Patient with negative IgG EBV serology.
- •Current or past (< 6 months) evidence of toxic megacolon, bowel obstruction or gastrointestinal perforation.
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
- •Known allergy or intolerance to trehalose or maltodextrin.
- •Vulnerable patients such as: minors, persons deprived of liberty, persons in Intensive Care Unit unable to provide informed consent prior to the intervention.
- •Females of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.
- •Breastfeeding females. Females of childbearing potential should be willing to use an acceptable method of birth control such as hormonal contraception (progestogen-only may be sufficient), male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide for the course of the study. A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods) are also considered acceptable. Females of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year.
- •Other ongoing interventional protocol that might interfere with the current study’s primary endpoint.
- •Patients with active CMV colitis
- •Patients who had previously received other lines of systemic aGvHD treatment other than CS and ruxolitinib.
- •Grade II-IV hyper-acute GvHD as defined by the MD Anderson’s criteria (Saliba et al. 2007) (aGvHD onset within 14 days after allo-HSCT)
- •Overlap chronic GvHD as defined by the NIH Consensus Criteria (Jagasia et al. 2015)
- •Relapsed/persistent malignancy requiring rapid immune suppression withdrawal
- •Active uncontrolled infection according to the attending physician
- •Severe organ dysfunction unrelated to underlying GvHD, including: - Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GvHD and ongoing organ dysfunction, with the exception of Gilbert syndrome). - Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months before Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support that requires therapy. - Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.
- •Current or past (< 6 months) veno-occlusive disease or other uncontrolled complication unless otherwise agreed in writing by the sponsor.
结局指标
主要结局
To evaluate the efficacy of MaaT013 assessed by the overall response rate (ORR) of gastrointestinal (GI) acute grfat-versus-host disease (aGVHD) response at day 28 (D28).
To evaluate the efficacy of MaaT013 assessed by the overall response rate (ORR) of gastrointestinal (GI) acute grfat-versus-host disease (aGVHD) response at day 28 (D28).
次要结局
- To evaluate MaaT013 safety
- To evalutae ORR for GI at D56 and M3
- To evaluate ORR for all organs at D28, D56 and M3
- To evaluate the best ORR (for GI and all organs) acheived between D0 and D28
- To assess duration of response
- To assess overall survival (OS)
- To assess progression-free survival (PFS)
- To assess time to progression
- To assess steroid-free survival
- To evaluate the frequency of patients that tapered off CS
- To measure the incidence of chronic GvHD
- To evaluate changes in patient reported outcomes (PROs)
研究者
Maat-Pharma Contact Point
Scientific
MaaT PHARMA
研究点 (50)
Loading locations...
相似试验
招募中
3 期
AMX0035 and Progressive Supranuclear Palsy2023-505893-14-00Amylyx Pharmaceuticals Inc.269
尚未招募
2 期
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabNeuroblastomaNCT07261241New Approaches to Neuroblastoma Therapy Consortium118
招募中
3 期
[68Ga]Ga-PentixaFor-PET imaging for staging of marginal zone lymphoma2022-500918-25-00Pentixapharm AG148
已完成
4 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
已完成
1 期
Phase 1b study to evaluate MK 0482 for Relapsed/Refractory AML/CMML2023-503580-42-00Merck Sharp & Dohme LLC15